The RAS/MAPK pathway, with an important role in cancer biology, is a prime target for anti-cancer agents; however, the presence of an NF1 mutation, resulting in reduced expression of neurofibromin, confers resistance to several therapeutic drugs. Here, NF1 is linked to cancer.